The Japanese company provides compound screening services for the discovery of small molecular drugs and target protein identification services. The ideal partners are EU pharmaceutical and biotech companies of any size in need of such type of services.
Small and medium sized pharmaceutical companies and biotech companies prefer to outsource their screening activities as they lack of in-house capabilities, while for large companies, even though in-house capabilities exist in their structures, they are insufficient to meet all their drug discovery needs especially for screening diversified compound libraries and specialized targets.
To solve above issues, the Japanese company has access to a library of one million diversified compounds with therefore more advanced expertise compared to similar service providers.
They are capable of:
- screening for targets that cannot be handled by conventional screening methods;
- screening for a backup target without extra charge if there is no hit for the priority target;
- targeting protein identification for unknown compounds.
The EU market structure is basically the same as the Japanese one, but thanks to the fact that the number of pharmaceutical and biotech companies is a lot higher than in Japan, the company is expecting further business opportunities in accessing it.
The company wishes to do business in a direct sales method in EU countries targeting pharmaceutical and biotech organizations to establish cooperation in terms of services agreement.
Since screening services offered by the company are consistently required in drug discoveries' processes, longer term partnerships are expected from this offer.